Cargando…

Impact of cryopreservation on CAR T production and clinical response

Adoptive cell therapy with chimeric antigen receptor (CAR) T cells has become an efficient treatment option for patients with hematological malignancies. FDA approved CAR T products are manufactured in centralized facilities from fresh or frozen leukapheresis and the cryopreserved CAR T infusion pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brezinger-Dayan, Karin, Itzhaki, Orit, Melnichenko, Jenny, Kubi, Adva, Zeltzer, Li-at, Jacoby, Elad, Avigdor, Abraham, Shapira Frommer, Ronnie, Besser, Michal J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582437/ https://www.ncbi.nlm.nih.gov/pubmed/36276077 http://dx.doi.org/10.3389/fonc.2022.1024362

Ejemplares similares

Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
por: Itzhaki, Orit, et al.
Publicado: (2020)

Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies
por: Beider, Katia, et al.
Publicado: (2022)

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
por: Rozenbaum, Meir, et al.
Publicado: (2020)

Nicotinamide Inhibits Vasculogenic Mimicry, an Alternative Vascularization Pathway Observed in Highly Aggressive Melanoma
por: Itzhaki, Orit, et al.
Publicado: (2013)

Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
por: Nissani, Abraham, et al.
Publicado: (2021)

P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA
por: Magen, Hila, et al.
Publicado: (2023)

P1400: THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE
por: Geva, Mika, et al.
Publicado: (2023)

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
por: Danylesko, Ivetta, et al.
Publicado: (2023)

Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy
por: Ortenberg, R., et al.
Publicado: (2015)

Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose
por: Gross, Golda, et al.
Publicado: (2023)

P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
por: Fried, S., et al.
Publicado: (2022)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy
por: Yunger, Sharon, et al.
Publicado: (2019)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

Anterior chamber infiltration of CAR T-cells
por: Jacoby, Elad, et al.
Publicado: (2021)

A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme
por: Galore-Haskel, Gilli, et al.
Publicado: (2015)

Murine Models of Acute Leukemia: Important Tools in Current Pediatric Leukemia Research
por: Jacoby, Elad, et al.
Publicado: (2014)

Predicting and controlling the reactivity of immune cell populations against cancer
por: Oved, Kfir, et al.
Publicado: (2009)

Genetic Modification of Tumor-Infiltrating Lymphocytes via Retroviral Transduction
por: Weinstein-Marom, Hadas, et al.
Publicado: (2021)

Il-6 is non-essential to murine CD19 CAR efficacy, but can mediate acute GVHD following allogeneic BMT with CAR T cell infusion
por: Jacoby, Elad, et al.
Publicado: (2015)

Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation
por: Seliktar-Ofir, Sivan, et al.
Publicado: (2017)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

A Metabolism Toolbox for CAR T Therapy
por: Xu, Xuequn, et al.
Publicado: (2019)

Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex
por: Greenberg, Eyal, et al.
Publicado: (2014)

Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
por: Garcia-Prieto, Carlos A, et al.
Publicado: (2021)

CAR-Based Approaches to Cutaneous T-Cell Lymphoma
por: Scarfò, Irene, et al.
Publicado: (2019)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

CAR T Cell Therapy for Pediatric Brain Tumors
por: Patterson, John D., et al.
Publicado: (2020)

Strategies for Dodging the Obstacles in CAR T Cell Therapy
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021)

Impact of the COVID-19 pandemic on ovarian tissue cryopreservation planning in the Bologna clinical center
por: Magnani, Valentina, et al.
Publicado: (2022)

Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers
por: Rossig, Claudia, et al.
Publicado: (2018)

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
por: Cheng, Jiali, et al.
Publicado: (2019)

CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future
por: Zhang, Zhengchao, et al.
Publicado: (2022)

Innovation in BCMA CAR-T therapy: Building beyond the Model T
por: Banerjee, Rahul, et al.
Publicado: (2022)

Advances in CAR T cell immunotherapy for paediatric brain tumours
por: Rao, Padmashree, et al.
Publicado: (2022)

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Modulating the proliferative and cytotoxic properties of patient-derived TIL by a synthetic immune niche of immobilized CCL21 and ICAM1
por: Yunger, Sharon, et al.
Publicado: (2023)

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h0uhs13rdmcuj1mf4p2d65re3a